Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
Janessa Laskin, Stephen V. Liu, Khaled A. Tolba, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1693-1703
Open Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

Advances in systemic therapy for non-small cell lung cancer
Meagan Miller, Nasser H. Hanna
BMJ (2021), pp. n2363-n2363
Closed Access | Times Cited: 240
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Alison M. Schram, Igor Odintsov, Madelyn Espinosa‐Cotton, et al.
Cancer Discovery (2022) Vol. 12, Iss. 5, pp. 1233-1247
Open Access | Times Cited: 117
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 74
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 64
Recent progress in targeted therapy for non-small cell lung cancer
Yanxia Xiao, Pu Liu, Jie Wei, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 47
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
Vincent D. de Jager, Wim Timens, Arnaud Bayle, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100839-100839
Open Access | Times Cited: 27
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
Dong‐Wan Kim, Alison M. Schram, Antoine Hollebecque, et al.
Future Oncology (2024) Vol. 20, Iss. 16, pp. 1057-1067
Open Access | Times Cited: 22
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Alison M. Schram, Kōichi Goto, Dong-Wan Kim, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 6, pp. 566-576
Closed Access | Times Cited: 8
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma
Jiao Li, Kaimeng Huang, Meha Thakur, et al.
Nature Metabolism (2025)
Closed Access | Times Cited: 3
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Alfredo Addeo, Antonio Passaro, Umberto Malapelle, et al.
Cancer Treatment Reviews (2021) Vol. 96, pp. 102179-102179
Open Access | Times Cited: 89
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
Barbara Melosky, Paul Wheatley‐Price, Rosalyn A. Juergens, et al.
Lung Cancer (2021) Vol. 160, pp. 136-151
Closed Access | Times Cited: 59
Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications
Daniel Kazdal, Véronique Hofman, Petros Christopoulos, et al.
Genes Chromosomes and Cancer (2022) Vol. 61, Iss. 5, pp. 244-260
Closed Access | Times Cited: 47
Precision cancer medicine: Concepts, current practice, and future developments
Anders Edsjö, Louise Holmquist, Birgit Geoerger, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 4, pp. 455-481
Open Access | Times Cited: 26
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
Brandon S. Sheffield, Kiefer Eaton, Bruno Émond, et al.
Current Oncology (2023) Vol. 30, Iss. 2, pp. 2348-2365
Open Access | Times Cited: 23
Omics-based molecular classifications empowering in precision oncology
Zhaokai Zhou, Ting Lin, Shuang Chen, et al.
Cellular Oncology (2024) Vol. 47, Iss. 3, pp. 759-777
Closed Access | Times Cited: 12
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis
Misako Nagasaka, Sai‐Hong Ignatius Ou
Trends in cancer (2022) Vol. 8, Iss. 3, pp. 242-258
Closed Access | Times Cited: 38
Neuregulin-1, a potential therapeutic target for cardiac repair
Yan Wang, Jian-Liang Wei, Peng Zhang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 38
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
James T. Topham, Erica S. Tsang, Joanna M. Karasinska, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions
Stephen V. Liu, Claas Frohn, Lori Ann E. Minasi, et al.
Lung Cancer (2024) Vol. 188, pp. 107469-107469
Open Access | Times Cited: 8
Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics
Tian‐Hua Wei, Meng‐Yi Lu, Sihui Yao, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 7
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
Birgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Cancer Discovery (2024) Vol. 15, Iss. 1, pp. 119-138
Open Access | Times Cited: 7
The promise of bispecific antibodies: Clinical applications and challenges
Sun Min Lim, Kyoung‐Ho Pyo, Ross A. Soo, et al.
Cancer Treatment Reviews (2021) Vol. 99, pp. 102240-102240
Closed Access | Times Cited: 37
Basket Trials: Review of Current Practice and Innovations for Future Trials
Brian P. Hobbs, Roberto Carmagnani Pestana, Emily C. Zabor, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 30, pp. 3520-3528
Open Access | Times Cited: 25
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
Jia Zhong, Hua Bai, Zhijie Wang, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 1, pp. 18-42
Closed Access | Times Cited: 14
IBPGNET: lung adenocarcinoma recurrence prediction based on neural network interpretability
Zhanyu Xu, Haibo Liao, Liuliu Huang, et al.
Briefings in Bioinformatics (2024) Vol. 25, Iss. 3
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top